|
The latest Mainline newsletters for the General Public are listed here. |
For healthcare professionals we have a Mainline newsletter in a Professional version here. |
Mainline |
||
| Volume 3 | August 24, 2006 | Number 7 |
An Exclusive Continuing Education Publication of Acadiana Consultant Pharmacy Service |
||
Medication News & Update
Weight-based, fixed-dose, unmonitored subcutaneous unfractionated heparin administered twice daily found to be equivalent to low molecular weight heparin for treatment of DVT and PE
Investigators in Canada and New Zealand randomized a total of 708 DVT and/or PE patients to twice daily, fixed dose unfractionated heparin (333 U/Kg load followed by 250 U/kg q 12 hrs) or twice daily subcutaneous LMWH (100 U/kg q 12 hrs - approximately 75% received dalteparin and 25% enoxaparin). Most patients (approx. 70% in each group) - including PE patients - were treated as outpatients. The trial was open-label but end points were adjudicated by a board that was blinded to treatment. There was no significant difference in recurrent VTE (3.8% with UFH vs. 3.4% with LMWH), major bleed (1.1% with UFH vs. 1.4% with LMWH), and deaths (18 in UFH vs 22 with LMWH).
The complete posting and a link to the full text of the article referenced is available on ClotCare at http://www.clotcare.com/clotcare/ufhvslmwhfordvtpe.aspx [2].
---------
|
[ Home ]
[ About Us ]
[ Assessment Tools ]
[ Sample Consult ] |
